Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: FASEB J. 2020 Mar 5;34(4):5877–5891. doi: 10.1096/fj.201903045RR

Fig 7.

Fig 7.

Model of Enzalutamide and Olaparib synergistically suppressing HCC. Enzalutamide (ENZ), as a selective antagonist of AR, inhibits AR binding with the promoter of miR-146a-5p and then increases its transcription. More miR-146a-5p targets the 3’UTR of BRCA1 mRNA. As a consequence, BRCA1 protein decreases. Loss of BRCA1 leads to HR deficiency. Olaparib targets PARP-1 leading to base excision repair (BER) deficiency. Combining ENZ with Olaparib will lead to irreparable DNA damage and cell death.